Published on
19:31 GMT
How Nasdaq became biotech’s default exchange — and why the IPO comeback is testing its value
On Oct. 23, Lycia Therapeutics made its Nasdaq debut and finished its first trading day up 66.7% from its IPO price. Two weeks earlier, Retension Pharmaceuticals had arrived on the same exchange to a different reception: Its shares fell 12.3% on their …
Source:
PharmaVoice
-
Neutral
